Skip to Content

Genprex Inc GNPX

Morningstar Rating

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

PR Newswire Apr 9, 2024 12:31pm
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

PR Newswire Apr 3, 2024 12:31pm
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System

PR Newswire Apr 2, 2024 12:31pm
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PR Newswire Mar 22, 2024 8:10pm
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PR Newswire Mar 19, 2024 5:24pm
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PR Newswire Mar 19, 2024 12:36pm
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

PR Newswire Mar 12, 2024 1:01pm
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

PR Newswire Mar 6, 2024 1:30pm
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

PR Newswire Feb 7, 2024 1:15pm
Genprex to Present at Upcoming BIO CEO & Investor Conference

PR Newswire Feb 6, 2024 12:30pm
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer

PR Newswire Feb 5, 2024 12:30pm
Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024

PR Newswire Jan 31, 2024 1:42pm
Genprex Shares Jump 14% Pre-Market on FDA Fast Track Designation

Global News Select Jun 28, 2023 1:33pm

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.